OvaScience Company Profile (NASDAQ:OVAS)

About OvaScience (NASDAQ:OVAS)

OvaScience logoOvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OVAS
  • CUSIP: N/A
  • Web: www.ovascience.com
Capitalization:
  • Market Cap: $52.1 million
  • Outstanding Shares: 35,686,000
Average Prices:
  • 50 Day Moving Avg: $1.51
  • 200 Day Moving Avg: $1.50
  • 52 Week Range: $1.25 - $8.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $465,000.00
  • Price / Sales: 112.05
  • Book Value: $2.27 per share
  • Price / Book: 0.64
Profitability:
  • EBIDTA: ($62,550,000.00)
  • Net Margins: -16,132.47%
  • Return on Equity: -69.13%
  • Return on Assets: -61.52%
Debt:
  • Current Ratio: 7.54%
  • Quick Ratio: 7.54%
Misc:
  • Average Volume: 420,470 shs.
  • Beta: 3.51
  • Short Ratio: 12.23
 

Frequently Asked Questions for OvaScience (NASDAQ:OVAS)

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

How were OvaScience's earnings last quarter?

OvaScience Inc. (NASDAQ:OVAS) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.02. The company earned $0.08 million during the quarter, compared to analysts' expectations of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The firm's revenue for the quarter was down 55.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.62) EPS. View OvaScience's Earnings History.

When will OvaScience make its next earnings announcement?

OvaScience is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for OvaScience.

Where is OvaScience's stock going? Where will OvaScience's stock price be in 2017?

3 brokerages have issued 12-month target prices for OvaScience's shares. Their forecasts range from $1.00 to $15.00. On average, they expect OvaScience's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for OvaScience.

Are investors shorting OvaScience?

OvaScience saw a decline in short interest in July. As of July 31st, there was short interest totalling 3,328,895 shares, a decline of 31.0% from the July 14th total of 4,825,999 shares. Based on an average daily trading volume, of 214,957 shares, the short-interest ratio is presently 15.5 days. Currently, 10.4% of the shares of the company are short sold.

Who are some of OvaScience's key competitors?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:

  • Michelle Dipp M.D. Ph.D., Executive Chairman of the Board, Acting President, Chief Executive Officer, Principal Executive Officer
  • Chris A. Kroeger M.D., Chief Executive Officer
  • Jonathan Gillis, principal Financial Officer, principal Accounting Officer, Vice President
  • Karen Long, Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance
  • James Luterman Ph.D., Executive Vice President - Research and Development
  • Theresa McNeely, Executive Vice President, Chief Communications Officer
  • Ravi Mehrotra Ph.D., Chief Corporate Development Officer
  • Richard H. Aldrich, Lead Independent Director
  • John P. Howe III M.D., Director
  • John E. Sexton Ph.D., Director

Who owns OvaScience stock?

OvaScience's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.89%), EcoR1 Capital LLC (9.84%), Jennison Associates LLC (6.14%), Vanguard Group Inc. (4.24%), Franklin Resources Inc. (1.78%) and Legal & General Group Plc (1.29%). Company insiders that own OvaScience stock include Jeffrey E Young, Marc D Kozin, Mary Fisher, Michelle Dipp, Paul WD Chapman and Richard Aldrich. View Institutional Ownership Trends for OvaScience.

Who sold OvaScience stock? Who is selling OvaScience stock?

OvaScience's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc., Virtu KCG Holdings LLC and FMR LLC. View Insider Buying and Selling for OvaScience.

Who bought OvaScience stock? Who is buying OvaScience stock?

OvaScience's stock was purchased by a variety of institutional investors in the last quarter, including Legal & General Group Plc, Broadfin Capital LLC, LMR Partners LLP, Zacks Investment Management, Susquehanna International Group LLP, Wells Fargo & Company MN and Jennison Associates LLC. Company insiders that have bought OvaScience stock in the last two years include Jeffrey E Young, Marc D Kozin, Mary Fisher, Michelle Dipp, Paul WD Chapman and Richard Aldrich. View Insider Buying and Selling for OvaScience.

How do I buy OvaScience stock?

Shares of OvaScience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OvaScience's stock price today?

One share of OvaScience stock can currently be purchased for approximately $1.46.


MarketBeat Community Rating for OvaScience (NASDAQ OVAS)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OvaScience (NASDAQ:OVAS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (447.95% upside)

Analysts' Ratings History for OvaScience (NASDAQ:OVAS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
5/12/2017HC WainwrightReiterated RatingBuy$15.00LowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingUnderperform -> Underperform$1.00LowView Rating Details
8/10/2016JMP SecuritiesReiterated RatingNeutralN/AView Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetNeutral$9.00 -> $8.00N/AView Rating Details
5/8/2016Leerink SwannReiterated RatingHold$6.00 -> $7.00N/AView Rating Details
3/21/2016S&P Equity ResearchLower Price Target$10.82 -> $8.83N/AView Rating Details
10/2/2015WedbushLower Price TargetOutperform$46.00 -> $15.00N/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for OvaScience (NASDAQ:OVAS)
Earnings by Quarter for OvaScience (NASDAQ:OVAS)
Earnings History by Quarter for OvaScience (NASDAQ OVAS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.39)N/AView Earnings Details
8/3/2017Q2 2017($0.47)($0.45)$0.09 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.46)($0.38)$0.12 million$0.06 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.58)($0.64)$0.11 million$0.12 millionViewListenView Earnings Details
11/3/2016Q316($0.62)($0.54)$0.25 million$0.02 millionViewListenView Earnings Details
8/4/2016Q216($0.78)($0.62)$0.21 million$0.19 millionViewListenView Earnings Details
5/5/2016Q116($0.72)($0.80)$0.14 million$0.15 millionViewListenView Earnings Details
2/25/2016Q315($0.71)($0.76)$0.20 million$0.16 millionViewListenView Earnings Details
11/5/2015Q3($0.68)($0.66)$0.17 million$0.08 millionViewN/AView Earnings Details
8/10/2015Q215($0.64)($0.64)$0.57 million$0.03 millionViewN/AView Earnings Details
5/11/2015($0.65)($0.65)$0.40 million$0.02 millionViewN/AView Earnings Details
3/16/2015Q414($0.59)($0.79)ViewN/AView Earnings Details
11/10/2014Q314($0.44)($0.54)ViewN/AView Earnings Details
8/7/2014Q214($0.45)($0.42)ViewN/AView Earnings Details
5/8/2014($0.46)($0.41)ViewN/AView Earnings Details
2/27/2014Q413($0.39)($0.64)ViewN/AView Earnings Details
11/13/2013Q313($0.35)($0.40)ViewN/AView Earnings Details
8/13/2013Q213($0.28)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OvaScience (NASDAQ:OVAS)
2017 EPS Consensus Estimate: ($1.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OvaScience (NASDAQ:OVAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OvaScience (NASDAQ:OVAS)
Insider Ownership Percentage: 12.59%
Institutional Ownership Percentage: 64.38%
Insider Trades by Quarter for OvaScience (NASDAQ:OVAS)
Institutional Ownership by Quarter for OvaScience (NASDAQ:OVAS)
Insider Trades by Quarter for OvaScience (NASDAQ:OVAS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Michelle DippCEOBuy425,000$7.00$2,975,000.00View SEC Filing  
5/18/2016Michelle DippCEOBuy20,000$7.86$157,200.00View SEC Filing  
5/17/2016Michelle DippCEOBuy40,000$7.63$305,200.00View SEC Filing  
5/13/2016Richard AldrichDirectorBuy36,095$6.94$250,499.30View SEC Filing  
5/11/2016Richard AldrichDirectorBuy20,000$7.64$152,800.00View SEC Filing  
5/10/2016Michelle DippCEOBuy19,900$7.72$153,628.00View SEC Filing  
5/10/2016Paul W.D. ChapmanCOOBuy3,100$7.37$22,847.00View SEC Filing  
3/24/2016Michelle DippCEOBuy59,800$9.49$567,502.00View SEC Filing  
3/22/2016Michelle DippCEOBuy59,800$10.44$624,312.00View SEC Filing  
3/18/2016Michelle DippCEOBuy59,700$8.26$493,122.00View SEC Filing  
3/16/2016Michelle DippCEOBuy59,029$7.90$466,329.10View SEC Filing  
3/14/2016Michelle DippCEOBuy162,732$7.60$1,236,763.20View SEC Filing  
10/5/2015Jeffrey E YoungCFOBuy3,450$10.70$36,915.00View SEC Filing  
10/5/2015Marc D KozinDirectorBuy4,800$10.79$51,792.00View SEC Filing  
9/9/2015Mary FisherDirectorBuy6,100$16.49$100,589.00View SEC Filing  
9/8/2015Marc D KozinDirectorBuy3,000$17.60$52,800.00View SEC Filing  
4/8/2015Marc D KozinDirectorBuy3,000$28.45$85,350.00View SEC Filing  
4/2/2015Michelle DippCEOBuy1,000$32.49$32,490.00View SEC Filing  
1/13/2015Thomas MalleyDirectorBuy35,000$50.00$1,750,000.00View SEC Filing  
7/7/2014Richard AldrichDirectorBuy2,000$9.49$18,980.00View SEC Filing  
6/30/2014Richard AldrichDirectorBuy2,000$9.16$18,320.00View SEC Filing  
6/23/2014Richard AldrichDirectorBuy2,000$8.81$17,620.00View SEC Filing  
6/16/2014Richard AldrichDirectorBuy2,000$8.52$17,040.00View SEC Filing  
6/9/2014Richard AldrichDirectorBuy2,000$7.59$15,180.00View SEC Filing  
6/3/2014Harald F StockDirectorBuy1,063$7.01$7,451.63View SEC Filing  
6/2/2014Richard AldrichDirectorBuy2,000$7.29$14,580.00View SEC Filing  
5/27/2014Richard AldrichDirectorBuy2,000$7.50$15,000.00View SEC Filing  
5/20/2014Harald F StockDirectorBuy1,050$7.13$7,486.50View SEC Filing  
5/19/2014Richard AldrichDirectorBuy2,000$7.33$14,660.00View SEC Filing  
3/7/2014Fund L.P. LongwoodMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
9/12/2013Arthur TzianabosInsiderBuy1,000$10.32$10,320.00View SEC Filing  
9/12/2013Harald F StockDirectorBuy4,500$10.64$47,880.00View SEC Filing  
9/11/2013Christopher A BleckInsiderBuy2,000$11.15$22,300.00View SEC Filing  
9/11/2013Richard AldrichDirectorBuy4,850$10.54$51,119.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OvaScience (NASDAQ:OVAS)
Latest Headlines for OvaScience (NASDAQ:OVAS)
Source:
DateHeadline
finance.yahoo.com logoEdited Transcript of OVAS earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 13 at 7:54 PM
americanbankingnews.com logoOvaScience Inc. (NASDAQ:OVAS) Sees Significant Decline in Short Interest
www.americanbankingnews.com - August 12 at 3:08 AM
americanbankingnews.com logo-$0.43 EPS Expected for OvaScience Inc. (NASDAQ:OVAS) This Quarter
www.americanbankingnews.com - August 12 at 2:14 AM
americanbankingnews.com logoAnalyzing Ampliphi Biosciences Corp (APHB) & OvaScience (NASDAQ:OVAS)
www.americanbankingnews.com - August 6 at 7:54 AM
americanbankingnews.com logoOvaScience Inc. (OVAS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 4 at 7:44 AM
reuters.com logoBRIEF-Ovascience Q2 loss per share $0.51
www.reuters.com - August 4 at 6:45 AM
finance.yahoo.com logoOvaScience Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 6:45 AM
finance.yahoo.com logoOvaScience reports 2Q loss
finance.yahoo.com - August 4 at 6:45 AM
americanbankingnews.com logoOvaScience Inc. (NASDAQ:OVAS) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - August 3 at 7:02 PM
businesswire.com logoOvaScience to Host Second Quarter 2017 Financial Results Conference Call - Business Wire (press release)
www.businesswire.com - July 29 at 6:08 AM
finance.yahoo.com logoOvaScience to Host Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 28 at 6:35 AM
americanbankingnews.com logoShort Interest in OvaScience Inc. (NASDAQ:OVAS) Grows By 34.3%
www.americanbankingnews.com - July 27 at 7:06 AM
americanbankingnews.com logoOvaScience Inc. (OVAS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 10 at 9:55 AM
americanbankingnews.com logoOppenheimer Holdings Brokers Cut Earnings Estimates for OvaScience Inc. (OVAS)
www.americanbankingnews.com - June 26 at 7:10 AM
streetinsider.com logoForm 4 OvaScience, Inc. For: Jun 21 Filed by: ALDRICH RICHARD - StreetInsider.com
www.streetinsider.com - June 24 at 7:37 PM
streetinsider.com logoForm 3 OvaScience, Inc. For: Jun 21 Filed by: GILLIS JONATHAN - StreetInsider.com
www.streetinsider.com - June 24 at 7:37 PM
americanbankingnews.com logoOvaScience Inc. (OVAS) Receives Hold Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 24 at 11:56 AM
streetinsider.com logoForm 4 OvaScience, Inc. For: Jun 21 Filed by: CAPELLO JEFFREY D - StreetInsider.com
www.streetinsider.com - June 24 at 12:48 AM
News IconBRIEF-OvaScience appoints Christopher Kroeger as CEO
www.businessinsider.com - June 23 at 8:51 AM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 8:51 AM
businesswire.com logoOvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - June 22 at 7:14 AM
finance.yahoo.com logoOvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer
finance.yahoo.com - June 22 at 7:14 AM
finance.yahoo.com logoWaltham’s OvaScience names new CEO, cuts half its staff
finance.yahoo.com - June 22 at 7:14 AM
finance.yahoo.com logoOvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - June 22 at 7:14 AM
streetinsider.com logoOvaScience (OVAS) Completes Enrollment in OvaPrime Clinical Study in Women with POI or POR
www.streetinsider.com - June 13 at 7:12 PM
americanbankingnews.com logoOvaScience Inc. (OVAS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 13 at 11:14 AM
seekingalpha.com logoOvaScience completes enrollment in OvaPrime study - Seeking Alpha
seekingalpha.com - June 13 at 10:34 AM
finance.yahoo.com logoOvaScience Completes Enrollment of 70 Patients in OvaPrime Clinical Study in Women with Primary Ovarian Insufficiency or Poor Ovarian Response
finance.yahoo.com - June 13 at 10:34 AM
finance.yahoo.com logoETFs with exposure to OvaScience, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 7:42 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Expected to Announce Quarterly Sales of $90,000.00
www.americanbankingnews.com - June 4 at 8:40 AM
finance.yahoo.com logoOvaScience, Inc. :OVAS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 9:21 PM
americanbankingnews.com logo Analysts Anticipate OvaScience Inc (OVAS) to Post -$0.44 Earnings Per Share
www.americanbankingnews.com - June 2 at 2:34 PM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 23 at 6:35 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 19 at 1:42 PM
americanbankingnews.com logoZacks Investment Research Lowers OvaScience Inc (OVAS) to Sell
www.americanbankingnews.com - May 13 at 7:52 AM
americanbankingnews.com logoOvaScience's (OVAS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 12 at 5:20 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for OvaScience Inc Cut by Oppenheimer Holdings (OVAS)
www.americanbankingnews.com - May 12 at 8:50 AM
seekingalpha.com logoOvaScience beats by $0.01, misses on revenue
seekingalpha.com - May 12 at 12:34 AM
americanbankingnews.com logoOvaScience Inc (OVAS) Expected to Post Quarterly Sales of $130,000.00
www.americanbankingnews.com - May 11 at 12:20 PM
americanbankingnews.com logoOvaScience Inc (OVAS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 7:40 PM
finance.yahoo.com logoEdited Transcript of OVAS earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:47 AM
finance.yahoo.com logoOvaScience Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 6:41 PM
finance.yahoo.com logoOvaScience reports 1Q loss
finance.yahoo.com - May 9 at 6:41 PM
americanbankingnews.com logo-$0.46 Earnings Per Share Expected for OvaScience Inc (OVAS) This Quarter
www.americanbankingnews.com - May 9 at 7:46 AM
americanbankingnews.com logoOvaScience Inc (OVAS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 7 at 6:26 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 5 at 7:22 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against OvaScience, Inc. (OVAS) and Lead Plaintiff Deadline - May 29, 2017
finance.yahoo.com - May 4 at 7:16 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Extremely Likely to Impact OvaScience (OVAS) Share Price
www.americanbankingnews.com - May 4 at 2:34 PM
businesswire.com logoOvaScience to Host First Quarter 2017 Financial Results Conference Call
www.businesswire.com - May 3 at 7:57 PM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in OvaScience, Inc. to Contact the Firm
finance.yahoo.com - May 2 at 4:52 PM

Social

Chart

OvaScience (OVAS) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff